Article Versions Notes

Wu K-L, Chen H-L, Tsai Y-M, Lee T-H, Chang H-M, Tsai Y-C, Chuang C-H, Chang Y-C, Tu Y-K, Yang C-J, et al. First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 2021; 10(19):4376. https://doi.org/10.3390/jcm10194376

Wu, Kuan-Li, Hsiao-Ling Chen, Ying-Ming Tsai, Tai-Huang Lee, Hsiu-Mei Chang, Yu-Chen Tsai, Cheng-Hao Chuang, Yong-Chieh Chang, Yu-Kang Tu, Chih-Jen Yang, and et al. 2021. "First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis" Journal of Clinical Medicine 10, no. 19: 4376. https://doi.org/10.3390/jcm10194376

Wu, K.-L., Chen, H.-L., Tsai, Y.-M., Lee, T.-H., Chang, H.-M., Tsai, Y.-C., Chuang, C.-H., Chang, Y.-C., Tu, Y.-K., Yang, C.-J., Hung, J.-Y., & Chong, I.-W. (2021). First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 10(19), 4376. https://doi.org/10.3390/jcm10194376